Medical device company Ivantis has added $25m to its Ascension-backed series B round, bringing the total raised in the round to $71m.

US-based Ivantis, the developer of a device to treat glaucoma patients, has raised an additional $25m from investors including corporate venturing unit Ascension Ventures to take its series B round to $71m.

Venture capital firms Foresite Capital, New Enterprise Associates (NEA), Delphi Ventures, Vertex Ventures and GBS Ventures, investment firm EDBI and investment fund MemorialCare Innovation Fund also participated. The funding will be used to support clinical trials for its Hydrus Microstent device.

This round adds to three previous series…